Daily News

FDA's New Framework For Streamlining RMAT Reg Requirements Offers Clarity, But Some Questions Remain

December 05, 2017
One of FDA's newest regenerative medicine advanced therapies (RMAT) draft guidances provides the regenerative medicine industry with much-needed regulatory clarity and consistency, according to the head of lobby group Alliance for Regenerative Medicine (ARM), but some questions remain. The group's head said it will be interesting to see how FDA steps up enforcement in the space and predicts manufacturing and standardization questions will pop up. FDA will allow certain RMAT-device combinations to be classified as combination products, but in the...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting as congressional Republicans take another run at repealing Obamacare.